JO2561B1 - Pharmaceutical composition comprising Progestogens and/or Estrogens and 5-methyl-(6S)-tetrahydrofolate - Google Patents

Pharmaceutical composition comprising Progestogens and/or Estrogens and 5-methyl-(6S)-tetrahydrofolate

Info

Publication number
JO2561B1
JO2561B1 JO2006133A JOP20060133A JO2561B1 JO 2561 B1 JO2561 B1 JO 2561B1 JO 2006133 A JO2006133 A JO 2006133A JO P20060133 A JOP20060133 A JO P20060133A JO 2561 B1 JO2561 B1 JO 2561B1
Authority
JO
Jordan
Prior art keywords
tetrahydrofolate
methyl
deficiency
folate
defects
Prior art date
Application number
JO2006133A
Other languages
Arabic (ar)
Inventor
ستروثمان كاي
وليش سميث جيفن
بلود هارتموت
كينج كريستينا
موزر رودولف
Original Assignee
باير شيرنج فارما اكتنجيسلشافت
ميرك ايبروفا ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by باير شيرنج فارما اكتنجيسلشافت, ميرك ايبروفا ايه جي filed Critical باير شيرنج فارما اكتنجيسلشافت
Application granted granted Critical
Publication of JO2561B1 publication Critical patent/JO2561B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition which comprises progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, can be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused by folate deficiency such as, for example, neural tube defects, ventricular valve defects, urogenital defects, and cleft lip, jaw and palate, without masking the symptoms of vitamin B12 deficiency, and at the same time even in the case of homozygous or heterozygous polymorphism of methylenetetrahydrofolate reductase facilitates unimpaired utilizability of the folate component 5-methyl-(6S); -tetrahydrofolate by the body and thus its biological activity for preventing the abovementioned congenital malformations caused by folate deficiency. In addition, a prolonged protective effect is maintained after discontinuation of the contraceptive.
JO2006133A 2005-05-13 2006-05-14 Pharmaceutical composition comprising Progestogens and/or Estrogens and 5-methyl-(6S)-tetrahydrofolate JO2561B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005023301A DE102005023301B4 (en) 2005-05-13 2005-05-13 Pharmaceutical composition containing progestogens and / or estrogens and 5-methyl- (6S) -tetrahydrofolate

Publications (1)

Publication Number Publication Date
JO2561B1 true JO2561B1 (en) 2010-11-03

Family

ID=37295493

Family Applications (2)

Application Number Title Priority Date Filing Date
JO2006133A JO2561B1 (en) 2005-05-13 2006-05-14 Pharmaceutical composition comprising Progestogens and/or Estrogens and 5-methyl-(6S)-tetrahydrofolate
JOP/2010/0287A JOP20100287B1 (en) 2005-05-13 2010-08-12 Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2010/0287A JOP20100287B1 (en) 2005-05-13 2010-08-12 Pharmaceutical compound containing gestagens and/or oestrogens and 5-methyl-(6S)-tetrahydrofolates

Country Status (3)

Country Link
DE (1) DE102005023301B4 (en)
JO (2) JO2561B1 (en)
UA (1) UA92491C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111973484A (en) 2013-03-12 2020-11-24 普莱玛疗法公司 Dental compositions comprising chelating agents and bases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693255A5 (en) * 1997-06-13 2003-05-15 Eprova Ag Use of tetrahydrofolates natürlichenstereoisomeren in the form suitable for the preparation of a pharmaceutical composition for influencing the homocysteine ​​level.
DE10022510A1 (en) * 2000-05-10 2001-11-15 Basf Ag Composition used as folate source in food, feed, nutritional supplements or medicaments, e.g. for prophylaxis of cardiovascular disease includes folic acid and 5-methyl-tetrahydrofolic acid
MXPA04008185A (en) * 2002-02-21 2004-11-26 Schering Ag Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12.

Also Published As

Publication number Publication date
DE102005023301B4 (en) 2012-05-31
JOP20100287B1 (en) 2022-03-14
UA92491C2 (en) 2010-11-10
DE102005023301A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
TW200711651A (en) Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
MY169516A (en) Pharmaceutical composition containing a tetrahydrofolic acid
WO2005079751A3 (en) Oral pharmaceutical compositions of candesartan cilexetil
WO2006002361A3 (en) 2-methylpropanamides and their use as pharmaceuticals
TW200621763A (en) Lactam compounds and their use as pharmaceuticals
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
CL2007001961A1 (en) Pharmaceutical composition containing a) 2.0 mg of dienogest and 0.015 mg of ethinylestradiol and (6s) -5-methyl-tetrahydrofolate and one or more excipient / vehicles; kit; use for femeneine contraception and reduce the risk of congenital malformations due to lack of folate in pregnancy.
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
EP1906968A4 (en) New regimens for oral monophasic contraceptives
JO2561B1 (en) Pharmaceutical composition comprising Progestogens and/or Estrogens and 5-methyl-(6S)-tetrahydrofolate
SG162829A1 (en) Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
TH105386B (en) Pharmaceutical constituents consisting of progestogens and / or estrogens and 5-methyl- (6S) -tetrahydrofolate.
NZ737002A (en) Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
TH105386A (en) Pharmaceutical constituents consisting of progestogens and / or estrogens and 5-methyl - (6S) -tetrahydrofolate.
CU20070252A7 (en) PHARMACEUTICAL COMPOSITION CONTAINING DROSPIRENONE, ETHYLESTRADIOL AND CALCIUM SALT OF 5-METHYL ACID- (6S) -TETRAHYDROPHOLIC
DE602006002328D1 (en) Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, processes for their preparation and the pharmaceutical compositions containing them
TH94755B (en) Pharmaceutical mixtures for contraception and for reducing the risk of congenital abnormalities
AR064602A1 (en) ORAL CONTRACEPTIVE NEBULIZER
EGAWA et al. Education for recruit workers at construction sites